Welcome to our dedicated page for Teleflex news (Ticker: TFX), a resource for investors and traders seeking the latest updates and insights on Teleflex stock.
Teleflex Incorporated (NYSE: TFX) is a global medical technology company whose news flow reflects its activity across anesthesia, emergency medicine, interventional cardiology and radiology, surgical, vascular access, and urology. Company announcements frequently highlight portfolio developments, clinical research, financial performance, and governance changes, giving investors and healthcare professionals insight into how the business is evolving.
Recent Teleflex news has included leadership transitions, with the Board appointing a long-serving director as Interim President and Chief Executive Officer and naming a new Chair of the Board, as well as updates on the search for a permanent CEO. The company has also reported on strategic portfolio actions, such as agreements to sell its Original Equipment Manufacturing and Development Services business and its acute care and interventional urology segments, reflecting a shift toward a more focused organization centered on core critical care and high-acuity hospital markets.
On the operational side, Teleflex regularly issues quarterly earnings releases and outlook updates, detailing revenue by region and global product category, along with commentary on non-GAAP measures like adjusted revenue and adjusted constant currency revenue growth. Dividend declarations and share repurchase authorizations are also communicated through press releases and associated SEC filings.
For those following clinical and product developments, Teleflex news covers topics such as the launch of the Barrigel™ rectal spacer in new markets and support for investigator-initiated trials like the DUBSTENT DIABETES study in interventional cardiology. Visitors to this TFX news page can review these updates in one place to understand how Teleflex’s strategy, portfolio, and financial profile are changing over time.
Teleflex reported fourth quarter revenues of $761.9 million, reflecting a 7.1% year-over-year increase. The GAAP diluted EPS was $2.69, up from $1.62, while adjusted diluted EPS rose to $3.60, marking a 10.8% increase. For 2022, the company expects GAAP revenue growth of 2.3% to 3.8% and adjusted EPS between $13.70 and $14.30. The respiratory divestiture is projected to affect growth, contributing a 1.6% headwind. Teleflex emphasized its strategy for sustainable growth and enhancement of margins amid operational challenges.
Teleflex has received FDA clearance for expanded use of its specialty catheters and coronary guidewires in chronic total occlusion percutaneous coronary interventions (CTO PCI). CTOs, affecting nearly 20% of patients, are significant blockages that lead to ischemia. The CTO-PCI study demonstrated a 93.3% technical success rate and over 75% procedural success, emphasizing the effectiveness of Teleflex's devices in complex cases. This advancement reflects Teleflex's commitment to innovative medical technologies that enhance patient outcomes.
Teleflex (NYSE: TFX) will host a conference call on February 24, 2022, at 8:00 a.m. Eastern Time to discuss its fourth quarter and full year 2021 financial results. Investors can register for the call via the provided link or access it through an audio webcast on Teleflex's website. A replay will be available later that day. Teleflex specializes in medical technologies aimed at enhancing health and quality of life through innovative solutions across various medical fields, including vascular access and emergency medicine.
Teleflex is set to have its Chairman, President, and CEO, Liam Kelly, speak at the 40th Annual J.P. Morgan Healthcare Conference on January 11, 2022, at 4:30 p.m. ET. The event will be accessible via a live audio webcast on the Teleflex investor relations website, along with presentation slides. Known for its innovative medical technologies aimed at improving health outcomes, Teleflex operates in diverse fields including vascular access, interventional cardiology, and emergency medicine. Further details can be found on their website.
Teleflex Incorporated has received reimbursement approval for its UroLift System to treat benign prostatic hyperplasia (BPH) in Japan, effective April 1, 2022. This minimally invasive procedure offers symptom relief and improved quality of life for men suffering from BPH. CEO Liam Kelly emphasized the strategic investment in UroLift's commercial capabilities in Japan, aiming to train medical staff by early 2022. The UroLift System, already used in over 300,000 cases worldwide, is expected to significantly benefit the over two million affected men in Japan.
Teleflex Incorporated (NYSE: TFX) has announced a worldwide recall of its Arrow-Trerotola™ Over-The-Wire PTD® Kit due to a defect where the inner lumen can detach from the device’s basket. This recall affects products manufactured between October 2019 and July 2021, classified as a Class I recall by the FDA. The company received seven complaints, with no reported long-term complications. Consumers are advised to discontinue use and return all affected products. The recall notice, including product codes and lot numbers, is available on their website.
Teleflex (NYSE: TFX) has been named the top large company in the MedReps.com Best Places to Work in Medical Sales 2022 survey. This marks the fifth consecutive year Teleflex has earned this honor. The survey, which included over 2,300 medical sales professionals, highlighted key factors such as pay, leadership, and culture as significant for employees when choosing an employer. Teleflex's leadership expressed pride in the award, emphasizing the company's commitment to innovation and employee engagement.
Teleflex Incorporated (NYSE: TFX) is participating in the Piper Sandler 33rd Annual Virtual Healthcare Conference from November 22 to December 2, 2021. A pre-recorded presentation will be available on their investor website at 10 AM ET on November 22. Additionally, 1x1 meetings are scheduled for December 2, which can be requested through Piper Sandler. Teleflex focuses on innovative medical technologies across various fields including vascular access and emergency medicine, aiming to enhance patient health and quality of life.
Teleflex has partnered with Explorer Surgical to enhance training for urologists using the UroLift® System. This collaboration introduces the Explorer Live digital platform, promoting remote learning and collaboration through an interactive digital playbook. Surgeons can access tailored surgical information, real-time education, and video capabilities during procedures. The UroLift System offers a minimally invasive solution for benign prostatic hyperplasia, improving patient outcomes and access to effective treatments.
Teleflex (NYSE: TFX) responded to the November 3, 2021, release of the CMS 2022 Medicare Physician Fee Schedule (MPFS) Final Rule, effective January 1, 2022. The rule reduces Non-Facility Practice Expense Relative Value Units, impacting reimbursement for over 600 procedures, including the UroLift System. CEO Liam Kelly expressed disappointment, noting potential patient migration to outpatient settings due to reimbursement changes. The UroLift CPT codes will see fee reductions of 8% and 11%, respectively, and a phased implementation over four years. Financial implications will be discussed in Q4 2021 results.